On Friday, Shares of Gilead Sciences Inc. (NASDAQ:GILD), gained 0.47% to $108.34.
Gilead Sciences, declared that the U.S. Food and Drug Administration (FDA) has approved Genvoya® (elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg or E/C/F/TAF) for the treatment of HIV-1 infection. Genvoya is the first TAF-based regimen to receive FDA approval.
Genvoya is indicated as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients 12 years of age and older who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA levels less than 50 copies per mL) on a stable antiretroviral regimen for at least six months with no history of treatment failure and no known substitutions associated with resistance to the individual components of Genvoya. No dosage adjustment of Genvoya is required in patients with estimated creatinine clearance greater than or equal to 30 mL per minute.
Genvoya has a boxed warning in its product label regarding the risks of lactic acidosis/severe hepatomegaly with steatosis, and post treatment acute exacerbation of hepatitis B.
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical need in North America, South America, Europe, and the Asia-Pacific. The company’s products comprise Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Harvoni, Sovaldi, Viread, and Hepsera products for the treatment of liver disease.
Shares of Whole Foods Market, Inc. (NASDAQ:WFM), inclined 3.32% to $31.11, during its last trading session.
Whole Foods Market, declared a new capital allocation strategy that reflects confidence in the Company’s future growth and cash flow generation, while expanding its commitment to return capital to shareholders.
As part of this strategy, the Company’s Board of Directors has authorized a new $1 billion share repurchase program, bringing the Company’s total share repurchase authorization to $1.3 billion. In addition, the Board declared a 4% improvement in the quarterly dividend to $0.135 per share from $0.13 per share, the Company’s fifth successive dividend improvement since reinstating the dividend in 2011. The next dividend is payable on January 26, 2016 to shareholders of record as of January 15, 2016. Since 2011, the Company has returned about $2.4 billion to shareholders through dividends and share repurchases.
As part of its capital structure strategy, the Company recently reached a $500 million five-year revolving credit facility. In addition, before the end of the first quarter, the Company intends to incur additional long-term debt of up to $1 billion. The amount and composition of this debt will depend on market conditions and capital allocation considerations at the time the debt is incurred. The Company may also incur additional short-term debt of up to $350 million, which would be repaid with proceeds from the long-term debt. Proceeds from any debt incurred would be used for general corporate purposes, counting the repurchase of stock. The Company’s intent is to spend the majority of the $1 billion buyback authorization in the first half of the fiscal year and anticipates the combined effects of the additional indebtedness and future share repurchases to be accretive to earnings per share in fiscal year 2016.
Whole Foods Market, Inc. operates as a retailer of natural and organic foods. The company’s stores offer produce and floral, grocery, meat, seafood, bakery, prepared foods and catering, coffee, tea, beer, wine, cheese, nutritional supplements, vitamins, and body care products, in addition to lifestyle products, counting books, pet products, and household products.
Finally, Zynga, Inc. (NASDAQ:ZNGA), ended its last trade with -0.39% loss, and closed at $2.57.
Zynga, have been given an average rating of “Hold” by the nineteen research firms that are presently covering the firm, AnalystRatings.NET reports. Two equities research analysts have rated the stock with a sell recommendation, twelve have issued a hold recommendation, three have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $3.33.
Zynga Inc. develops, markets, and operates online social games as live services played on the Internet, social networking sites, and mobile platforms in the United States, Asia, and Europe. The company offers its online social games under the FarmVille, Words With Friends, Zynga Poker, Hit It Rich! Slots, CSR Racing, FarmVille 2: Country Escape, NFL Showdown, New Zynga Poker, New Words With Friends, Wizard of Oz Slots, Looney Tunes Dash!, CSR Classics, and Clumsy Ninja names.